Dongwu Securities released a research report on April 23 stating that it maintains the purchase rating of Fangsheng Pharmaceuticals (603998.SH). The main reasons for the rating include: 1) the steady release of 338 strategic products, and the outstanding performance of innovative traditional Chinese medicine varieties; 2) focusing on investment in R&D and innovation to reserve medium- to long-term growth momentum. (Mainichi Keizai Shimbun)
东吴证券4月23日发布研报称，维持方盛制药（603998.SH）买入评级。评级理由主要包括：1）338战略产品稳步放量，中药创新药品种表现亮眼；2）注重研发创新投入，储备中长期增长动能。（每日经济新闻）
Dongwu Securities released a research report on April 23 stating that it maintains the purchase rating of Fangsheng Pharmaceuticals (603998.SH). The main reasons for the rating include: 1) the steady release of 338 strategic products, and the outstanding
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.